结核病治疗期间体重增加增加了结核病后代谢综合征的风险
Argita D Salindri1, Teona Avaliani2, Mariam Gujabidze2
1Department of Population Health Sciences, Georgia State University School of Public Health, Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA, USA; and Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
medRxiv : the preprint server for health sciences
|December 8, 2025
概括
结核病治疗期间体重增加增加了治疗后发生代谢综合征的风险. 这一发现强调了在结核病治疗期间和之后监测身体质量指数 (BMI) 变化的重要性,以减轻长期心血管风险.
科学领域:
- 医学研究 医学研究
- 公共卫生 公共卫生
- 代谢性疾病研究研究.
背景情况:
- 结核病 (TB) 治疗期间体重增加与随后心脏代谢疾病风险之间的关系尚不清楚.
- 代谢综合征是心脏代谢疾病的重要预测因素.
研究的目的:
- 评估结核病治疗期间身体质量指数 (BMI) 变化与治疗后代谢综合征的患病率之间的关联.
- 研究体重增加对结核病后代谢健康的影响.
主要方法:
- 在格鲁吉亚 (2019-2022) 接受结核病治疗的120名个人的前性队列研究.
- 暴露量:从治疗开始到完成,BMI的相对变化 (≥5%的增加 vs. <5%的增加).
- 结果:结核病治疗后发生的代谢综合征 (≥3个组成部分:血压升高,甘油三,低HDL,HbA1c升高,腹部肥胖) 的发生率,评估时间长达12个月.
主要成果:
- 结核病治疗期间BMI相对增加≥5%与结核病后代谢综合征调整后风险增加2.07倍有关.
- 体重指数增加≥5%的个体在结核病后的调整平均HbA1c显著更高 (0.37个点高).
结论:
- 结核病治疗期间体重增加与患代谢综合征的风险增加有关.
- 这些发现表明,在结核病治疗期间监测BMI变化对于预测和潜在地预防未来心脏代谢并发症至关重要.
相关概念视频
Pulmonary Tuberculosis I
806
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
806
Pulmonary Tuberculosis V
527
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
527
Pulmonary Tuberculosis III
899
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
899
Pulmonary Tuberculosis IV
468
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
468
Pulmonary Tuberculosis II
1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
225
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
225


